{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T22:21:47Z","timestamp":1744496507153,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T00:00:00Z","timestamp":1720569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["CO-US-380-4644","CO-US-380-4644","CO-US-380-4644"],"award-info":[{"award-number":["CO-US-380-4644","CO-US-380-4644","CO-US-380-4644"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The rapid start of antiretroviral therapy (RSA) model initiates antiretroviral therapy (ART) as soon as possible after a new or preliminary diagnosis of HIV, in advance of HIV-1 RNA and other baseline laboratory testing. This observational study aims to determine if RSA with a single tablet regimen of bictegravir, emtricitabine, and tenofovir alafenamide (B\/F\/TAF) is an effective regimen for achieving viral suppression and accepted by patients at the time of diagnosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adults newly or preliminarily diagnosed with HIV were enrolled from October 2018 through September 2021. Real world advantage, measured in days between clinical milestones and time to virologic suppression, associated with B\/F\/TAF RSA was compared to historical controls.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>All Study RSA participants (<jats:italic>n<\/jats:italic>\u2009=\u200945) accepted treatment at their first visit and 43(95.6%) achieved virologic suppression by week 48. Study RSA participants had a significantly shorter time (median 32 days) from diagnosis to ART initiation and virologic suppression, in comparison to historical controls (median 181 days) (<jats:italic>n<\/jats:italic>\u2009=\u200942). Qualitative feedback from study RSA participants showed high acceptance positive response to RSA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>RSA is feasible and well accepted by patients in a real-world community-based clinic setting. Promoting RSA in community-based clinics is an important tool in ending the HIV epidemic.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12981-024-00631-6","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T17:02:14Z","timestamp":1720630934000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real world community-based HIV Rapid Start Antiretroviral with B\/F\/TAF versus prior models of antiretroviral therapy start \u2013 the RoCHaCHa study, a pilot study"],"prefix":"10.1186","volume":"21","author":[{"given":"William","family":"Valenti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Scutaru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Mancenido","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Zuppelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Danforth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Corales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shealynn","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,10]]},"reference":[{"key":"631_CR1","unstructured":"New York State Department of Health. Ending the AIDS Epidemic in New York State. https:\/\/www.health.ny.gov\/diseases\/aids\/ending_the_epidemic\/ (2023). Accessed September 8, 2023."},{"key":"631_CR2","unstructured":"Office of Infectious Disease and, Policy HIVAIDS. HHS: HIV.gov, Overview. https:\/\/www.hiv.gov\/federal-response\/ending-the-hiv-epidemic\/overview (2023). Accessed September 8, 2023."},{"issue":"9","key":"631_CR3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","volume":"373","author":"JD Lundgren","year":"2015","unstructured":"INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795\u2013807. https:\/\/doi.org\/10.1056\/NEJMoa1506816.","journal-title":"N Engl J Med"},{"issue":"7","key":"631_CR4","doi-asserted-by":"publisher","first-page":"e1002357","DOI":"10.1371\/journal.pmed.1002357","volume":"14","author":"SP Koenig","year":"2017","unstructured":"Koenig SP, Dorvil N, D\u00e9vieux JG, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLoS Med. 2017;14(7):e1002357. https:\/\/doi.org\/10.1371\/journal.pmed.1002357. Published 2017 Jul 25.","journal-title":"PLoS Med"},{"issue":"1","key":"631_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/QAD.0000000000001671","volume":"32","author":"N Ford","year":"2018","unstructured":"Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS. 2018;32(1):17\u201323. https:\/\/doi.org\/10.1097\/QAD.0000000000001671.","journal-title":"AIDS"},{"issue":"9","key":"631_CR6","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJMoa1507198","volume":"373","author":"C Danel","year":"2015","unstructured":"TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A trial of early antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1507198.","journal-title":"N Engl J Med"},{"key":"631_CR7","doi-asserted-by":"publisher","unstructured":"Rosen S, Maskew M, Fox MP et al. Initiating Antiretroviral Therapy for HIV at a Patient\u2019s First Clinic Visit: The RapIT Randomized Controlled Trial [published correction appears in PLoS Med. 2016;13(6):e1002050]. PLoS Med. 2016;13(5):e1002015. Published 2016 May 10. https:\/\/doi.org\/10.1371\/journal.pmed.1002015.","DOI":"10.1371\/journal.pmed.1002015"},{"key":"631_CR8","doi-asserted-by":"publisher","unstructured":"Coffey S, Bacchetti P, Sachdev D et al. RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population [published correction appears in AIDS. 2019;33(13):2113]. AIDS. 2019;33(5):825\u2013832. https:\/\/doi.org\/10.1097\/QAD.0000000000002124.","DOI":"10.1097\/QAD.0000000000002124"},{"issue":"1","key":"631_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/QAI.0000000000001134","volume":"74","author":"CD Pilcher","year":"2017","unstructured":"Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The Effect of same-day observed initiation of antiretroviral therapy on HIV viral load and Treatment Outcomes in a US Public Health setting. J Acquir Immune Defic Syndr. 2017;74(1):44\u201351. https:\/\/doi.org\/10.1097\/QAI.0000000000001134.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"631_CR10","doi-asserted-by":"publisher","first-page":"e033246","DOI":"10.1136\/bmjopen-2019-033246","volume":"9","author":"YC Huang","year":"2019","unstructured":"Huang YC, Sun HY, Chuang YC, et al. Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-centre retrospective cohort in Taiwan. BMJ Open. 2019;9(9):e033246. https:\/\/doi.org\/10.1136\/bmjopen-2019-033246. Published 2019 Sep 20.","journal-title":"BMJ Open"},{"key":"631_CR11","doi-asserted-by":"publisher","unstructured":"Gomillia CES, Backus KV, Brock JB, Melvin SC, Parham JJ, Mena LA. Rapid Antiretroviral Therapy (ART) Initiation at a Community-Based Clinic in Jackson, MS. AIDS Res Ther. 2020;17(1):60. Published 2020 Oct 8. https:\/\/doi.org\/10.1186\/s12981-020-00319-7.","DOI":"10.1186\/s12981-020-00319-7"},{"issue":"11","key":"631_CR12","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1097\/QAD.0000000000002937","volume":"35","author":"P Pathela","year":"2021","unstructured":"Pathela P, Jamison K, Braunstein SL, et al. Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression. AIDS. 2021;35(11):1805\u201312. https:\/\/doi.org\/10.1097\/QAD.0000000000002937.","journal-title":"AIDS"},{"issue":"10107","key":"631_CR13","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390(10107):2073\u201382. https:\/\/doi.org\/10.1016\/S0140-6736(17)32340-1.","journal-title":"Lancet"},{"key":"631_CR14","unstructured":"Gilead, Sciences. U.S. Food and Drug Administration Approves Gilead\u2019s Biktarvy\u00ae (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection. https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2018\/2\/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv1-infection (2018). Accessed December 14, 2022."},{"key":"631_CR15","unstructured":"Mulato A, Acosta R, Yant SR et al. Forgiveness of Antiretroviral Regimens: In Vitro HIV-1 Viral Breakthrough with 2-Drug versus 3-Drug Regimens Simulating Variable Adherence to Treatment. Proceedings of the 10th IAS Conference on HIV Science; 21\u201324 July 2019; Mexico City, Mexico. https:\/\/programme.ias2019.org\/PAGMaterial\/eposters\/1090.pdf."},{"key":"631_CR16","unstructured":"Bachelard A, Isernia V, Charpentier C et al. Efficacy and safety of using bictegravir \/ emtricitabine \/ tenofovir alafenamide (BIC\/FTC\/TAF) in a test and treat model: the FAST Study. Proceedings of the 18th European AIDS Clinical Society Conference; October 27\u201330, 2021; London, United Kingdom. https:\/\/www.abstractserver.com\/eacsabstractarchive\/absabstract.php?abid=8469."},{"issue":"9","key":"631_CR17","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1056\/NEJMoa1600693","volume":"375","author":"MS Cohen","year":"2016","unstructured":"Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the Prevention of HIV-1 transmission. N Engl J Med. 2016;375(9):830\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1600693.","journal-title":"N Engl J Med"},{"key":"631_CR18","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents. Plasma HIV-1 RNA (Viral Load) and CD4 Count Monitoring. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services. https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv (2023). Accessed January 6, 2023."},{"key":"631_CR19","unstructured":"Fine S, Vail R, McGowan J et al. Virologic and Immunologic Monitoring in HIV Care. 19. New York State Department of Health AIDS Institute, June 2016, Updated June 16, 2022. https:\/\/www.hivguidelines.org\/antiretroviral-therapy\/cd4-and-viral-load-monitoring\/#tab_0. Accessed December 15, 2022."},{"issue":"1","key":"631_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s40545-021-00385-w","volume":"14","author":"D Prieto-Merino","year":"2021","unstructured":"Prieto-Merino D, Mulick A, Armstrong C, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers\u2019 datasets. J Pharm Policy Pract. 2021;14(1):113. https:\/\/doi.org\/10.1186\/s40545-021-00385-w. Published 2021 Dec 29.","journal-title":"J Pharm Policy Pract"},{"key":"631_CR21","volume-title":"RStudio: Integrated Development for R. RStudio","author":"RStudio Team","year":"2020","unstructured":"RStudio Team. RStudio: Integrated Development for R. RStudio. Boston, MA URL: PBC; 2020. http:\/\/www.rstudio.com\/."},{"issue":"1","key":"631_CR22","doi-asserted-by":"publisher","first-page":"010502","DOI":"10.11613\/BM.2021.010502","volume":"31","author":"CC Serdar","year":"2021","unstructured":"Serdar CC, Cihan M, Y\u00fccel D, et al. Sample size, power and effect size revisited: simplified and practical approaches in pre-clinical, clinical and laboratory studies. Biochem Med (Zagreb). 2021;31(1):010502. https:\/\/doi.org\/10.11613\/BM.2021.010502. Published 2021 Feb 15.","journal-title":"Biochem Med (Zagreb)"},{"key":"631_CR23","unstructured":"Alere, Determine\u2122. HIV\u20131\/2 Ag\/Ab Combo [package insert]. Scarborough, ME: Abbott Diagnostics Scarborough, Inc. (2021). https:\/\/www.fda.gov\/vaccines-blood-biologics\/approved-blood-products\/determine-hiv-12-agab-combo. Accessed December 15, 2022."},{"key":"631_CR24","unstructured":"Radix AE, Fine SM, Vail RM et al. NYSDOH AIDS Institute Guideline: Rapid Art Initiation (2023). https:\/\/www.hivguidelines.org\/guideline\/hiv-art-rapid\/?mycollection=hiv-treatment."},{"key":"631_CR25","unstructured":"WHO: Guidelines for Managing Advanced HIV Disease and Rapid Initiation of ART. (2017) https:\/\/www.who.int\/hiv\/pub\/guidelines\/advanced-HIV-disease\/en\/."}],"container-title":["AIDS Research and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00631-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12981-024-00631-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12981-024-00631-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T17:03:48Z","timestamp":1720631028000},"score":1,"resource":{"primary":{"URL":"https:\/\/aidsrestherapy.biomedcentral.com\/articles\/10.1186\/s12981-024-00631-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,10]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["631"],"URL":"https:\/\/doi.org\/10.1186\/s12981-024-00631-6","relation":{},"ISSN":["1742-6405"],"issn-type":[{"type":"electronic","value":"1742-6405"}],"subject":[],"published":{"date-parts":[[2024,7,10]]},"assertion":[{"value":"26 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol and informed consent forms were reviewed and approved by WCG IRB (Puyallup, WA). All participants provided written informed consent at their first visit before being enrolled on study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the study, author M.M. was on the speaker bureau for ViiV Healthcare and author W.V. was a speaker for Gilead Sciences. Author R.C. was a medical scientist who represented Gilead Sciences in this collaborative study. Authors J.S., A.Z., and M.M. were affiliated with Trillium Health at study initiation and during data collection, but not at time of publication. Author J.S. is currently affiliated with CHEMED, 1771 Madison Ave, Lakewood, NJ 08701. Author A.Z. is currently affiliated with US Medical Affairs, Merck Research Laboratories, Kenilworth, NJ 07033, United States. Author M.M. is currently affiliated with Rochester Regional Health, Rochester, NY, United States.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"45"}}